한글목차

울토미리스 의약품의 주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동 인사이트, 시장 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 PNH에서 울토미리스의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시된 치료법)

제4장 경쟁 구도(후기 신규 치료법)

제5장 울토미리스 시장 평가

• PNH에서 울토미리스의 시장 전망
• 주요 7시장 분석
  • 주요 7 시장 PNH용 울토미리스의 시장 규모
• 시장 분석 : 국가별
  • 미국의 PNH용 울토미리스의 시장 규모
  • 독일의 PNH용 울토미리스의 시장 규모
  • 영국의 PNH용 울토미리스의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"ULTOMIRIS Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets. A detailed picture of the ULTOMIRIS for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ULTOMIRIS for PNH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.

Drug Summary:

ULTOMIRIS is a complement inhibitor for treating adult patients with PNH. It is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in several therapeutic areas, including hematology, nephrology, and neurology. It is a humanized monoclonal antibody that effectively blocks terminal complement activity at prescribed doses. ULTOMIRIS is the first and only long-acting C5 inhibitor that provides immediate and complete inhibition for 8 weeks.

Mechanism of action

Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS description, mechanism of action, dosage and administration, research and development activities in paroxysmal nocturnal hemoglobinuria (PNH).
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ULTOMIRIS research and development activities in PNH across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ULTOMIRIS.
• The report contains forecasted sales of ULTOMIRIS for PNH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PNH.
• The report also features the SWOT analysis with analyst views for ULTOMIRIS in PNH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

• In-depth ULTOMIRIS Market Assessment

This report provides a detailed market assessment of ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• ULTOMIRIS Clinical Assessment

The report provides the clinical trials information of ULTOMIRIS for PNH covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for paroxysmal nocturnal hemoglobinuria (PNH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
• Other emerging products for PNH are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in PNH.
• Our in-depth analysis of the forecasted sales data of ULTOMIRIS from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in PNH.

Key Questions

• What is the product type, route of administration and mechanism of action of ULTOMIRIS?
• What is the clinical trial status of the study related to ULTOMIRIS in paroxysmal nocturnal hemoglobinuria (PNH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS development?
• What are the key designations that have been granted to ULTOMIRIS for PNH?
• What is the forecasted market scenario of ULTOMIRIS for PNH?
• What are the forecasted sales of ULTOMIRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ULTOMIRIS for PNH?
• Which are the late-stage emerging therapies under development for the treatment of PNH?

Table of Contents

1. Report Introduction

2. ULTOMIRIS Overview in PNH

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ULTOMIRIS Market Assessment

• 5.1. Market Outlook of ULTOMIRIS in PNH
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ULTOMIRIS in the 7MM for PNH
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ULTOMIRIS in the United States for PNH
  • 5.3.2. Market Size of ULTOMIRIS in Germany for PNH
  • 5.3.3. Market Size of ULTOMIRIS in France for PNH
  • 5.3.4. Market Size of ULTOMIRIS in Italy for PNH
  • 5.3.5. Market Size of ULTOMIRIS in Spain for PNH
  • 5.3.6. Market Size of ULTOMIRIS in the United Kingdom for PNH
  • 5.3.7. Market Size of ULTOMIRIS in Japan for PNH

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options